About Us

What differentiates Myriad RBM from its competitors is that we have spent over 20 years internally developing and manufacturing multiplex immunoassays validated to clinical laboratory standards for the Luminex xMAP® technology. Since 2014, we have applied these skills to building ultrasensitive immunoassays on the Simoa™ platform to quantify protein biomarkers previously difficult or impossible to measure. The Myriad RBM platform appropriately combines Luminex and Simoa microsphere-based immunoassays with the precision and dependability of automated liquid handling systems, advanced quality monitoring, validated data reporting processes, and a highly-trained and dedicated staff including project managers. Together these features set Myriad RBM apart from other biomarker testing laboratories by providing the highest quality, cost-effective approach to measuring biomarkers from a variety of biological samples.

Myriad RBM’s CLIA certified biomarker testing laboratory, is located in Austin, TX and is a wholly owned subsidiary of Myriad Genetics, Inc. (MYGN), a leading molecular diagnostic company based in Salt Lake City, Utah which develops and markets novel predictive, personalized, and prognostic medicine tests.

Quality and Accreditation

We’ve designed our laboratory and component systems to deliver the highest quality data and to comply with the highest industry standards. Myriad RBM maintains a CLIA certificate of accreditation, performs internal audits, and participates in a proficiency-testing program comprised of external and internal assessments to ensure quality throughout the organization. We invite our customers to visit and audit our facility to review our high quality operations, procedures, and processes.

Our policies are in compliance with the applicable portions of the following regulations:

  • Good Laboratory Practices (21 CFR Part 58)
  • Quality System Regulation (21 CFR Part 820)
  • Electronic Signatures and Records (21 CFR Part 11)
  • Clinical Laboratory Improvement Amendments [CLIA] (42 CFR Part 493)
  • Good Clinical Practice (ICH E6)

Learn More »

Management Team

Myriad RBM is a wholly owned subsidiary of Myriad Genetics of Salt Lake City, UT.

To see the Myriad Genetics Management Team please click here

James P. Mapes, Ph.D.

James P. Mapes, Ph.D.

Sr. Vice President, Chief Scientific Officer

Sam LaBrie, VP Corporate Development

Samuel T. LaBrie, Ph.D.

Sr. Vice President, Corporate Development

Dominic Eisinger, Ph.D.

Dominic Eisinger, Ph.D.

Vice President, Sales & Marketing

Margaret Sandefur, Ph.D.

Margaret Sandefur, Ph.D.

Vice President, Quality Assurance and Regulatory Compliance

Karri Ballard, Senior Director Clinical Research

Karri Ballard, Ph.D.

Sr. Director, Clinical Research

Dennis Denton, VP IS Technology

Dennis Denton

Vice President, Information Systems & Technology

Kelley Nitka Ph.D.

Kelley Nitka, Ph.D., HCLD

Sr. Director of Lab Operations

Quality Policy

Myriad RBM is committed to the highest level of quality in our product. Quality and customer satisfaction shall underlie all of our efforts.


Myriad RBM has earned CLIA licensure of accreditation from COLA, participates in external proficiency testing programs from CAP, and is capable of supporting Good Laboratory Practice (GLP) studies.


Myriad RBM’s CLIA certified biomarker testing laboratory is located in Austin, TX. Myriad RBM is a wholly owned subsidiary of Myriad Genetics, Inc.

Institute Pasteur